Co-Authors
This is a "connection" page, showing publications co-authored by MICHELLE A.T. HILDEBRANDT and ROBERT ORLOWSKI.
Connection Strength
0.483
-
Genetic determinants of multiple myeloma risk within the Wnt/beta-catenin signaling pathway. Cancer Epidemiol. 2021 08; 73:101972.
Score: 0.203
-
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018 Dec; 5(12):e628-e640.
Score: 0.170
-
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. Int J Cancer. 2023 01 15; 152(2):239-248.
Score: 0.055
-
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma? Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1863-1866.
Score: 0.055